ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus recommendation of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $97.2857.

A number of research analysts have recently commented on ANIP shares. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. HC Wainwright increased their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Piper Sandler reiterated an “overweight” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. increased their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday.

ANI Pharmaceuticals Stock Down 0.3%

Shares of ANIP opened at $93.05 on Friday. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. The company has a market cap of $2.02 billion, a P/E ratio of -120.84 and a beta of 0.63. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The firm has a 50 day simple moving average of $85.56 and a two-hundred day simple moving average of $72.22.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $211.37 million during the quarter, compared to analysts’ expectations of $187.18 million. During the same period in the prior year, the company earned $1.02 EPS. ANI Pharmaceuticals’s revenue was up 53.2% compared to the same quarter last year. Research analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Matthew J. Leonard sold 2,528 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the sale, the director directly owned 6,864 shares in the company, valued at $622,015.68. This represents a 26.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, September 19th. The shares were sold at an average price of $98.04, for a total value of $98,040.00. Following the completion of the sale, the senior vice president owned 60,186 shares of the company’s stock, valued at $5,900,635.44. The trade was a 1.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 413,830 shares of company stock valued at $36,495,294 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its position in ANI Pharmaceuticals by 68.3% during the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock valued at $10,565,000 after acquiring an additional 64,021 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in ANI Pharmaceuticals by 53.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock valued at $599,000 after acquiring an additional 3,112 shares during the last quarter. Invesco Ltd. boosted its position in ANI Pharmaceuticals by 1.0% during the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock valued at $13,361,000 after acquiring an additional 2,022 shares during the last quarter. GAMMA Investing LLC boosted its position in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after acquiring an additional 881 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in ANI Pharmaceuticals by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock valued at $15,959,000 after acquiring an additional 2,220 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.